Please login to the form below

Not currently logged in
Email:
Password:

spinal muscular atrophy

This page shows the latest spinal muscular atrophy news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

The latest deal comes shortly after Novartis agreed a $8.7bn deal to acquire AveXis, a US specialist in spinal muscular atrophy (SMA).

Latest news

  • Roche drug hits the mark in spinal muscular atrophy studies Roche drug hits the mark in spinal muscular atrophy studies

    Roche drug hits the mark in spinal muscular atrophy studies. Data suggests Risdiplam could improve motor function. ... Roche has positive clinical data on its risdiplam candidate in spinal muscular atrophy (SMA), suggesting it could add to the emerging

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    Pfizer abandons antibody for Duchenne. Pfizer has halted development of its Duchenne muscular dystrophy (DMD) candidate domagrozumab on disappointing results in a mid-stage efficacy trial. ... Biogen is however focusing initially on spinal muscular

  • Shock as NICE turns down Biogen’s SMA therapy Shock as NICE turns down Biogen’s SMA therapy

    After a delay in starting its review of Biogen’s spinal muscular atrophy drug Spinraza, NICE has further disappointed patients and carers by rejecting the drug in draft guidance. ... Spinal muscular atrophy can be devastating and today’s news will be

  • Spinraza keeps Biogen buoyant ahead of Alzheimer’s data Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

    A leap in sales driven by spinal muscular atrophy drug Spinraza sent Biogen shares upwards yesterday, but those gains could be reversed or boosted by much-anticipated Alzheimer’s data due

  • Novartis buys gene therapy firm AveXis for $8.7bn Novartis buys gene therapy firm AveXis for $8.7bn

    The Swiss pharma group is paying $218 per share in cash for the US biotech and its lead gene therapy candidate for spinal muscular atrophy (SMA), with the price tag more

More from news
Approximately 6 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to.

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US ... 2015 and in the EU 2016) and Spinraza (for the

  • Deal Watch August 2016 Deal Watch August 2016

    95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.

  • Deal Watch July 2016 Deal Watch July 2016

    In 2014 the partners expanded the agreement for CK-2127107 to include some neuromuscular indications, such as Spinal Muscular Atrophy (SMA).

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Raising Awareness: Rare Disease Day

    of, such as spinal muscular atrophy and lysosomal storage disorders.(3). ... confused for other diseases.(2) For example, the genetic disorder adrenomyeloneuropathy, characterized by progressive problems with the brain, spinal cord and peripheral nerves

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics